Fatores de risco associados ao desenvolvimento da dor neuropática induzida por quimioterapia.

Abstract

Among the chemotherapy complications, peripheral chemotherapy-induced neuropathy (CIPN) is the most common neurological syndrome secondary to cancer therapy and may have a profound impact on quality of life and the possibility to adversely affect cancer outcomes. Objectives: To identify risk factors for peripheral neuropathy in cancer patients undergoing chemotherapy outpatients followed at Hospital Universitário Alcides Carneiro (HUAC) and Fundação Assistencial da Paraíba (FAP). Methods: This was an analytical crosssectional observational uncontrolled study with a sample of 102 patients treated with chemotherapy. The combination of patient characteristics and the chemotherapy regimen with the presence of peripheral neuropathy measured by LANSS scale. For it used the χ2 test association and Fisher's exact test, when necessary, considering the significance level of 5%. To determine the strength of association, calculated the odds ratio (OR) and its confidence interval of 95% (95%). Results: It was found that the use of chemotherapy alone the nitrogen mustards classes and antitumor antibiotics is shown as a risk factor for the development of peripheral neuropathy (OR: 3.74; 95% CI: 1.24 to 11.24 / OR : 3.13; 95% CI: 1.5 to 9.34 respectively), but after multiple logistic regression showed that association not static significance. Discussion: The prevalence of neuropathic pain in the sample is 15.7%. Risk factors associated with the development of pain likely neuropathic (SLANSS≥12) identified in our sample were the use of nitrogen mustards and antitumor antibiotics. However, after multiple logistic regression hierarchic this association did not persist with statistical significance in the final model. Conclusion: The prevalence of peripheral neuropathy induced by chemotherapy proved compatible with the assessed literature. Taken together they were not presented risk or protective factors for the development of CIPN.